Mindray Medical announces completion of Wuhan Dragonbio acquisition

Mindray Medical International Limited ("Mindray" or the "Company", NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today that it completed the acquisition of the remaining stake in Wuhan Dragonbio Surgical Implant Co., Ltd. (the "Dragonbio") for a total cash consideration of RMB 435 million (approximately US$ 70.2 million) pursuant to the terms of the definitive agreement entered into on July 7, 2015. The Company now holds 100% of Dragonbio. Dragonbio is a domestic medical orthopedic products provider that specializes in trauma, spine, joint and other surgical products.

Source:

Mindray Medical International Limited

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mindray. (2019, June 20). Mindray Medical announces completion of Wuhan Dragonbio acquisition. News-Medical. Retrieved on August 11, 2020 from https://www.news-medical.net/news/20150717/Mindray-Medical-announces-completion-of-Wuhan-Dragonbio-acquisition.aspx.

  • MLA

    Mindray. "Mindray Medical announces completion of Wuhan Dragonbio acquisition". News-Medical. 11 August 2020. <https://www.news-medical.net/news/20150717/Mindray-Medical-announces-completion-of-Wuhan-Dragonbio-acquisition.aspx>.

  • Chicago

    Mindray. "Mindray Medical announces completion of Wuhan Dragonbio acquisition". News-Medical. https://www.news-medical.net/news/20150717/Mindray-Medical-announces-completion-of-Wuhan-Dragonbio-acquisition.aspx. (accessed August 11, 2020).

  • Harvard

    Mindray. 2019. Mindray Medical announces completion of Wuhan Dragonbio acquisition. News-Medical, viewed 11 August 2020, https://www.news-medical.net/news/20150717/Mindray-Medical-announces-completion-of-Wuhan-Dragonbio-acquisition.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Mindray net revenues increase 8.9% to $334.5 million in Q2 2014